573
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

, , , , , , , , ORCID Icon, , , , , ORCID Icon, , , , , & show all
Pages 473-477 | Received 13 Jul 2022, Accepted 03 Nov 2022, Published online: 14 Dec 2022
 

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This work supported by National Institutes of Health/National Cancer Institute Grant Awards U10CA180888, U10CA180819, U10CA180821, U10CA180863, UG1CA233198, UG1CA233328, UG1CA189821, UG1CA233339, P30CA076292, UG1CA233193, and UG1CA189830. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.